Skip to main content
. 2024 Oct 29;14(21):2406. doi: 10.3390/diagnostics14212406

Figure 6.

Figure 6

Area under the curve (left) and normalized importance analysis (right) of the investigated biomarkers on ESA resistance (Legend: L-FABP—L-type fatty acid binding protein; TAFI—thrombin activatable fibrinolysis inhibitor; VEGF—vascular endothelial growth factor; AFP—alpha-fetoprotein; IL-6—interleukin-6; proBNP—prohormone of brain natriuretic peptide; tPA—tissue-type plasminogen activator; MP—microparticles; FGF-23—fibroblast growth factor-23; Ang2—angiopoietin 2; ADAMTS-13—a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; vWF—von Willebrand factor; TNF-α—tumor necrosis factor-alpha; MPO—myeloperoxidase; eGAGs—endogenous glycosaminoglycans; NEFA—non-esterified fatty acids; CRP—C-reactive protein; PAI-1—plasminogen activator inhibitor-1; PF4—platelet factor 4; IgG—immunoglobulin G; LPS—lipopolysaccharide; fPAI-1—functional plasminogen activator inhibitor-1; NT- nitrotyrosine).